https://pubmed.ncbi.nlm.nih.gov/38640348/
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory...
Ivosidenib is a first-in-class mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor with efficacy and tolerability in patients with advanced mIDH1 hematologic...
https://scholars.duke.edu/publication/1657106
Scholars@Duke publication: INNV-07. IVOSIDENIB AND BEVACIZUMAB IN HEAVILY PRETREATED PATIENTS WITH...
https://pubmed.ncbi.nlm.nih.gov/41842958/
The allosteric IDH1 inhibitor ivosidenib overcomes chemoresistance in intrahepatic...
Gemcitabine-based chemotherapy is the standard treatment regime for advanced intrahepatic cholangiocarcinoma (iCCA), but the frequent presence of...
allostericinhibitor
https://pubmed.ncbi.nlm.nih.gov/33119479/
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly...
Ivosidenib plus azacitidine was well tolerated, with an expected safety profile consistent with monotherapy with each agent. Responses were deep and durable,...
isocitrate dehydrogenase
https://scholars.duke.edu/publication/1412012
Scholars@Duke publication: Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid...
https://adisinsight.springer.com/drugsafety/803456225?error=cookies_not_supported&code=4a9e4076-4e6a-4592-9d45-48cbdebc659d
Cytarabine/ivosidenib/venetoclax - AdisInsight
A case series described, a 63-year-old man, who developed septic shock and multi-organ failure secondary to pulmonary Mycobacterium avium complex infection
cytarabinevenetoclaxadisinsight